Cryoablation Devices have emerged as an effective medical device for the treatment of various cancers and arrhythmias
Single-use cryoablation
devices are designed for treating single tumor sites with great
flexibility and portability. These devices can be easily integrated into
existing clinical work or can be used in on-site treatment facilities.
Single-use devices provide excellent tumor control and management for lung
cancers, skin cancers, pancreatic cancer, ovarian cancer, leukemia, bone
cancers, head and neck cancers, cervical cancers, and other solid tumors.
Localized cryoablation is a process of injecting high-temperature gas in the
direction of the tumor to destroy the affected tissues. This process results in
the CO2 injection, which aids in localizing the tumor and preventing its spread
to other areas.
A local progression of the disease is
prevented because the heat generated damages tumor cells and prevents them from
replicating. This therapy has good control over metastasis. Its effects are most
effective during the first one to three weeks of treatment and the
post-operative symptoms are also relieved. Risks of the procedure include
allergic reactions, which include signs and symptoms such as swelling, redness,
itching, peeling, and cracking. In case of hypothermia, seizures and fever may
occur. Patients who have had no prior surgery and those with an increased risk
of developing complications are at a higher risk of complications.
When the procedure is performed under
general anesthesia, complications are rare. However, if the inoperable stage is
reached before the medication dose has reached the targeted site, there is a
high risk of mortality. A very common complication after cryoablation is
diarrhea. Some patients develop a profusely watery discharge. A less common
complication after anesthesia is an infection of the treated area or of the
peritoneum or the abdomen. A very rare complication, however, is death from
ventricular tachycardia or cardiomyopathy caused by oxygen deprivation. Recently,
in June 2021, Medtronic received the U.S. Food and Drug Administration (FDA)
approval for its Arctic Front Family of Cardiac Cryoablation catheters to treat
recurrent symptomatic paroxysmal atrial fibrillation (AF).
Comments
Post a Comment